Molecular Medicine: The Molecule Biz (2 of 3)
Wednesday, March 31st, 2004In the previous installment about the molecular medicine conference, I emphasized that the science of so-called complex, polygenic diseases like cancer is, well, complex. But there are other complications as well in the life science business. Biotechnology and pharmaceuticals are also risky, complicated enterprises from a financial standpoint. In a way it’s kind of a [...]


